Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Capital Expenditures (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of Capital Expenditures data on record, last reported at $27000.0 in Q3 2025.

  • For Q3 2025, Capital Expenditures fell 69.66% year-over-year to $27000.0; the TTM value through Sep 2025 reached $271000.0, down 12.86%, while the annual FY2024 figure was $230000.0, 64.01% down from the prior year.
  • Capital Expenditures reached $27000.0 in Q3 2025 per UTMD's latest filing, down from $51000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $321000.0 in Q3 2022 and bottomed at $9000.0 in Q4 2024.
  • Average Capital Expenditures over 5 years is $131157.9, with a median of $90000.0 recorded in 2023.
  • Peak YoY movement for Capital Expenditures: crashed 97.8% in 2021, then soared 2270.0% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $253000.0 in 2021, then plummeted by 84.98% to $38000.0 in 2022, then soared by 136.84% to $90000.0 in 2023, then crashed by 90.0% to $9000.0 in 2024, then soared by 200.0% to $27000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $27000.0 in Q3 2025, $51000.0 in Q2 2025, and $184000.0 in Q1 2025.